Cartesian Therapeutics (NASDAQ: RNAC) granted employment inducement stock options to eight new employees, effective July 1, 2026. The awards cover an aggregate 238,700 common shares at an exercise price of $10.18, matching the Nasdaq Global Market closing price on the grant date.
The options, issued under the Amended and Restated 2018 Employment Inducement Incentive Award Plan and approved by the board, vest 25% on July 1, 2027 with the remainder vesting in 36 monthly installments through July 1, 2030, and have a ten-year term under Nasdaq Rule 5635(c)(4).
On the day this news was published, RNAC gained 4.03%, reflecting a moderate positive market reaction.
Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
This price movement added approximately $12M to the company's valuation, bringing the market cap to $321.73M at that time.
The company’s grant of 238,700 inducement options at an exercise price matching the $10.18 close rep...
Analysis
The company’s grant of 238,700 inducement options at an exercise price matching the $10.18 close represents routine equity-based hiring compensation, following similar awards earlier in 2026; investors may focus more on upcoming clinical and financing milestones than this HR-related item.
Key Figures
Inducement option shares:238,700 sharesExercise price:$10.18Employees receiving grants:8 employees+4 more
7 metrics
Inducement option shares238,700 sharesAggregate options granted to eight new employees on July 1, 2026
Exercise price$10.18Exercise price equal to July 1, 2026 Nasdaq Global Market close
Employees receiving grants8 employeesNumber of new hires receiving inducement awards
Initial vesting dateJul 1, 202725% of options vest on this date
Inducement options for five new employees totaling 317,200 shares at $6.22 exercise.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news reactions have been mixed, with slightly more events aligning with the tone of the announcements than diverging.
Regulatory & Risk Context
Short Interest: 14.19%
Short Interest
14.19% of float
0%15%30%+
moderateas of 2026-06-15Days to cover: 3.24
Short interest is moderately elevated, implying that sentiment shifts or unexpected news could translate into sharper price swings than in a lightly shorted stock.
Key Terms
employment inducement incentive award plan, nasdaq global market, nasdaq listing rules
3 terms
employment inducement incentive award planfinancial
"granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan"
An employment inducement incentive award plan is a program that gives new hires upfront or time‑based rewards—often company stock, options or cash—designed to persuade talent to join and stay. Think of it as a signing bonus that vests over time to align the new employee’s interests with the company’s future performance. Investors care because these awards create ongoing costs and can dilute existing ownership, while shaping management incentives and retention.
nasdaq global marketfinancial
"the closing trading price of the Company’s common stock on the Nasdaq Global Market"
The Nasdaq Global Market is a section of the stock exchange where larger, well-established companies are listed and publicly traded. It functions like a marketplace where investors can buy and sell shares of these companies, providing them with access to capital and opportunities for growth. Its role is important because it helps investors identify and invest in reputable companies with strong financial backgrounds.
nasdaq listing rulesregulatory
"under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement"
Nasdaq listing rules are the rulebook a company must follow to have its shares traded on the Nasdaq stock exchange, covering entry requirements and ongoing standards for finances, corporate governance, public disclosure and reporting. For investors they matter because the rules create baseline checks — like a driver’s license and regular inspections for a car — that promote transparency, comparability and reduce the risk of fraud or sudden delisting.
FREDERICK, Md., July 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to eight new employees. On July 1, 2026, the Company issued to these employees options to purchase an aggregate of 238,700 shares of the Company’s common stock with an exercise price of $10.18, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant.The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors.The options vest as to 25% on July 1, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the options will be fully vested on July 1, 2030. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees’ entry into employment with the Company.
About Cartesian Therapeutics
Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X.
What employment inducement grants did Cartesian Therapeutics (NASDAQ: RNAC) announce on July 2, 2026?
Cartesian Therapeutics announced stock option inducement grants to eight new employees, covering 238,700 shares at a $10.18 exercise price. According to Cartesian Therapeutics, these options were approved by the board and granted under its Amended and Restated 2018 Employment Inducement Incentive Award Plan.
What is the exercise price of the new RNAC inducement stock options?
The exercise price of the new inducement options is $10.18 per share. According to Cartesian Therapeutics, this price equals the closing trading price of its common stock on the Nasdaq Global Market on July 1, 2026, the grant date for these awards.
How do Cartesian Therapeutics' July 2026 inducement options vest for new employees?
The inducement options vest 25% on July 1, 2027, then monthly thereafter. According to Cartesian Therapeutics, the remaining 75% vests in 36 substantially equal monthly installments, so the options become fully vested on July 1, 2030, subject to continued employment.
What is the term of the new RNAC inducement stock options granted in July 2026?
The inducement stock options have a ten-year term from the July 1, 2026 grant date. According to Cartesian Therapeutics, this means holders may exercise vested options up to ten years after grant, subject to plan and employment conditions.
Under which plan and Nasdaq rule were the July 2026 RNAC inducement options granted?
The options were granted under the Amended and Restated 2018 Employment Inducement Incentive Award Plan. According to Cartesian Therapeutics, they were issued pursuant to Nasdaq Listing Rule 5635(c)(4) as an inducement material to the employees’ entry into employment with the company.
How many shares are covered by Cartesian Therapeutics' July 2026 inducement option grants?
The July 2026 inducement grants cover options to purchase an aggregate 238,700 shares of common stock. According to Cartesian Therapeutics, these options were issued to eight new employees as part of their employment inducement compensation package.
